Breast
ReadyBreast cancer spheroids evaluated with commercial drugs as a benchmark. A 15-patient panel captures the spectrum of subtypes (ER+, HER2+, TNBC) and their genetic variations.
Bio-Organoids
Tumours, grown true to the patient
OrgCan™ cancer organoids — patient-derived, microenvironment-aware models for personalized drug screening, biomarker discovery and immuno-oncology.
OrgCan™ organoids
Tumours, grown true to the patient
OrgCan™ cancer organoids are derived directly from patient biopsies or specialised cell lines — preserving the genetic, genomic and phenotypic character of real human tumours.
Patient relevance
Derived from human donors for superior clinical predictability.
High predictivity
Faithfully replicates patient response to drug candidates.
Tumour heterogeneity
Maintains the cellular composition of the original tissue.
Novel biomarkers
Ideal for discovery and validation of new clinical markers.
Ready for collaboration
BreastColorectalMelanoma
Available on request
OvarianOralProstateLungUterineBladderPancreaticHCC / Liver
Dermal Papillary Organoids
DFSCs + keratinocytes + fibroblasts in Matrigel — hair growth, anti-graying, strengthening.
Tonsil Organoids
Lymphoepithelial architecture for immune activation, cell & gene therapy studies.
BioDOrg — Tumour-in-Tissue
Tumour organoids cultured within reconstructed human tissue for microenvironment-accurate response.
Featured collection
Breast Cancer Patient-Derived Panel
15 unique patient-derived organoids capturing ER+, HER2+ and TNBC subtypes and their genetic variation.
Live 3D · drag-free, auto-rotating
- High-throughput compound screening
- Toxicity & efficacy of candidate molecules
- Biomarker discovery & validation
- TME co-culture (PBMCs, TILs, TAMs)
Cancer types
Six cancers in detail — plus 9+ available on request
Each programme combines patient-derived organoids with the right benchmark, microenvironment and readout for clinically relevant predictions.
Colorectal
ReadyColorectal organoids preserving glandular morphology — for chemotherapy response, targeted therapy, and resistance profiling.
Melanoma
ReadyMelanoma tissue model engineered with mutated cancer cell lines integrated into reconstructed human tissue — direct evaluation of novel oncological therapies.
Pancreatic
On requestAdenocarcinoma-like glandular morphology — for targeted drug-sensitivity testing and resistance profiling.
Hepatocellular Carcinoma (HCC)
On requestHCC organoids to evaluate novel therapeutics against standard-of-care (e.g. sorafenib). Includes HepG2-based liver spheroids expressing CYP450 enzymes for hepatotoxicity and DMPK profiling.
Ovarian
On requestPDL1 expression analysis; standardised tumour-NK (Natural Killer) models for advanced immunotherapy screening and combination evaluation.
Patient-derived programme?
From biopsy intake to insight in 7–14 days. We'll scope the assay, run the panel and deliver the data — yours to take to clinic.